Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Correlation of Patient-Reported Outcomes with Red Blood Cell Transfusion Reduction and Rise in Hemoglobin in Patients with Lower-Risk Myelodysplastic Syndromes in the IMerge Trial

Mikkael A. Sekeres, Valeria Santini, Amer M. Zeidan, Uwe Platzbecker, Rami S. Komrokji, Maria Diez-Campelo, Pierre Fenaux, Michael R. Savona, Yazan F. Madanat, David Valcarcel, Antoine Regnault, Kristin Creel, Nishan Sengupta, Souria Dougherty, Sheetal Shah, Libo Sun, Ying Wan, Shyamala Navada, Esther Natalie Oliva

Blood (2024) 144 (Supplement 1): 3210.

https://doi.org/10.1182/blood-2024-199636

Published: 2024

Journal Articles

Effect of Prior Treatments on the Clinical Activity of Imetelstat in Transfusion-Dependent Patients with Erythropoiesis-Stimulating Agent, Relapsed or Refractory/Ineligible Lower-Risk Myelodysplastic Syndromes

Blood (2024) 144 (Supplement 1): 352.

https://doi.org/10.1182/blood-2024-203612

Published: 2024

Journal Articles

Improvement of Patient-Reported Outcomes Among Heavily Pretreated Patients with Lower-Risk Myelodysplastic Syndromes and High Transfusion Burden Treated with Imetelstat on the IMerge Phase 3 Trial

Mikkael A. Sekeres, Maria Diez-Campelo, Amer M. Zeidan, Uwe Platzbecker, Antoine Regnault, Kristin Creel, Nishan Sengupta, Ying Wan, Libo Sun, Qi Xia, Tymara Berry, Souria Dougherty, Sheetal Shah, Shyamala Navada, Valeria Santini, David Valcárcel

Blood (2023) 142 (Supplement 1): 6479.

https://doi.org/10.1182/blood-2023-181103

Published: 2023

Journal Articles

Imetelstat Achieved Prolonged, Continuous Transfusion Independence (TI) in Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndrome (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs) within the IMerge Phase 2 Study

Blood (2022) 140 (Supplement 1): 1106–1108.

https://doi.org/10.1182/blood-2022-169050

Published: 2022

Journal Articles

A Phase 1, Multicenter Study of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Patients with Proteasome Inhibitor Exposed and Lenalidomide-Refractory Myeloma (Trial MM-005)

Paul G. Richardson, MD, Craig Hofmeister, Noopur S. Raje, MD, David Siegel, MD PhD, Sagar Lonial, MD, Jacob P. Laubach, Yvonne A Efebera, MD, David H. Vesole, MD, Ajay K Nooka, Jacalyn Rosenblatt, Mohamed H Zaki, Jennifer Herring, Yan Li, PhD, Sheetal Shah, Min S Chen, Kenneth C Anderson

Blood (2015) 126 (23): 3036.

https://doi.org/10.1182/blood.V126.23.3036.3036

Published: 2015

Journal Articles

MM-005: A Phase 1 Trial Of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone (PVD) In Relapsed and/Or Refractory Multiple Myeloma (RRMM)

Paul G. Richardson, MD, Craig C. Hofmeister, MD, David Siegel, MD, PhD, Sagar Lonial, MD, Jacob P. Laubach, MD, Yvonne A. Efebera, MD, David H. Vesole, MD, PhD, Ajay K. Nooka, MD, MPH, Jacalyn Rosenblatt, MD, MSc, Noopur Raje, MD., Mohamed H. Zaki, MD, PhD, Ye Hua, MD, MPH, Yan Li, PhD, Sheetal Shah, BA, Jianming Wang, PhD, Kenneth C. Anderson, MD

Blood (2013) 122 (21): 1969.

https://doi.org/10.1182/blood.V122.21.1969.1969

Published: 2013

Journal Articles

Pomalidomide In Sickle Cell Disease: Phase I Study Of a Novel Anti-Switching Agent

Abdullah Kutlar, MD, Paul S. Swerdlow, MD, Steffen E. Meiler, MD, Kavita Natrajan, MBBS, Leigh G Wells, MSN, RN, FNP-BC, Betsy Clair, Sheetal Shah, BA, Robert Knight, MD

Blood (2013) 122 (21): 777.

https://doi.org/10.1182/blood.V122.21.777.777

Published: 2013

Journal Articles

MM-005: A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma

Paul G. Richardson, MD, Craig C. Hofmeister, MD, David Siegel, MD, PhD, Sagar Lonial, MD, Mohamad Zaki, MD, PhD, Ye Hua, MD, MPH, Sheetal Shah, BA, Jianming Wang, PhD, Kenneth C. Anderson, MD

Blood (2012) 120 (21): 727.

https://doi.org/10.1182/blood.V120.21.727.727

Published: 2012

Journal Articles

Final Results of the Phase I Study of Lenalidomide In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL-001 Study)

Blood (2010) 116 (21): 1376.

https://doi.org/10.1182/blood.V116.21.1376.1376

Published: 2010

Journal Articles

Preliminary Results of a Phase 1/2, Multi-Center, Open-Label Study (CLL- 001) Investigating a Stepwise Dose-Escalation Schedule of Lenalidomide in Relapsed or Refractory Chronic Lymphocytic Leukemia.

Clemens M Wendtner, MD, Daruka Mahadevan, MD, PhD, Stephan Stilgenbauer, MD, PhD, Olga Frankfurt, MD, Adrian Bloor, PhD, MRCP, FRCPath, Francesc Bosch, MD, PhD, Lutz Uharek, Richard R Furman, MD, Marco Gobbi, John G. Gribben, MD, DSc, Eva K. Kimby, MD, PhD, Mikkael A. Sekeres, MD, MS, Larry D. Cripe, MD, Elyane Lombardy, Sheetal Shah, Laure A Moutouh-de Parseval, Asher Alban Chanan-Khan, MD, Robert D. Knight, MD

Blood (2008) 112 (11): 2104.

https://doi.org/10.1182/blood.V112.11.2104.2104

Published: 2008

NARROW

Correlation of Patient-Reported Outcomes with Red Blood Cell Transfusion Reduction and Rise in Hemoglobin in Patients with Lower-Risk Myelodysplastic Syndromes in the IMerge Trial

Effect of Prior Treatments on the Clinical Activity of Imetelstat in Transfusion-Dependent Patients with Erythropoiesis-Stimulating Agent, Relapsed or Refractory/Ineligible Lower-Risk Myelodysplastic Syndromes

Improvement of Patient-Reported Outcomes Among Heavily Pretreated Patients with Lower-Risk Myelodysplastic Syndromes and High Transfusion Burden Treated with Imetelstat on the IMerge Phase 3 Trial

Imetelstat Achieved Prolonged, Continuous Transfusion Independence (TI) in Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndrome (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs) within the IMerge Phase 2 Study

A Phase 1, Multicenter Study of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Patients with Proteasome Inhibitor Exposed and Lenalidomide-Refractory Myeloma (Trial MM-005)

MM-005: A Phase 1 Trial Of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone (PVD) In Relapsed and/Or Refractory Multiple Myeloma (RRMM)

Pomalidomide In Sickle Cell Disease: Phase I Study Of a Novel Anti-Switching Agent

MM-005: A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma

Final Results of the Phase I Study of Lenalidomide In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL-001 Study)

Preliminary Results of a Phase 1/2, Multi-Center, Open-Label Study (CLL- 001) Investigating a Stepwise Dose-Escalation Schedule of Lenalidomide in Relapsed or Refractory Chronic Lymphocytic Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only